Abstract
SARS-CoV-2 diagnostics that report viral RNA concentrations can be used to determine a patient’s stage of infection, but this potential has not yet been realized due to a lack of prospective longitudinal data to calibrate such inferences. Here, we report the viral RNA trajectories for 68 individuals using quantitative PCR testing. On average, symptomatic and asymptomatic individuals reached similar peak viral RNA concentrations (22.2 Ct, 95% credible interval [19.1, 25.1] vs. 22.4 Ct [20.2, 24.5]) within similar amounts of time (2.9 days [0.7, 4.7] vs. 3.0 days [1.3, 4.3]), but acute shedding lasted longer for symptomatic individuals (10.5 days [6.5, 14.0] vs. 6.7 days [3.2, 9.2]). A second test within 2 days after an initial positive PCR result reliably indicated whether viral RNA concentration was increasing, decreasing, or in a low-level persistent phase. Quantitative viral RNA assessment, informed by viral trajectory, can improve algorithms for clinical and public health management.
Competing Interest Statement
JW is an employee of Quest Diagnostics. JW is an employee of Bioreference Laboratories.
Funding Statement
This study was funded by the NWO Rubicon 019.181EN.004 (CBFV), a clinical research agreement with the NBA and NBPA (NDG), the Huffman Family Donor Advised Fund (NDG), Fast Grant funding support from the Emergent Ventures at the Mercatus Center, George Mason University (NDG), and the Morris-Singer Fund for the Center for Communicable Disease Dynamics at the Harvard T.H. Chan School of Public Health (YHG).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In accordance with the guidelines of the Yale Human Investigations Committee, this work with de-identified samples was approved for research not involving human subjects by the Yale Internal Review Board (HIC protocol # 2000028599). This project was designated exempt by the Harvard IRB (IRB20-1407).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Code and data are available at https://github.com/gradlab/CtTrajectories
